Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisory | Zendy

Snyder David S. | Zendy; McMahon Ross | Zendy; Cohen Sandra R. | Zendy; Slovak Marilyn L. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisory

Author(s) -

Snyder David S.,

McMahon Ross,

Cohen Sandra R.,

Slovak Marilyn L.

Publication year - 2004

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.10456

Subject(s) - imatinib , myeloid leukemia , medicine , breakpoint cluster region , fusion gene , abl , cancer research , leukemia , oncology , tyrosine kinase , biology , gene , receptor , genetics

A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR‐ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response. Am. J. Hematol. 75:92–95, 2004. © 2004 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research